NASDAQ:MIRO • US60471P1084
The current stock price of MIRO is 3.39 USD. In the past month the price increased by 1.5%. In the past year, price increased by 17.71%.
ChartMill assigns a technical rating of 8 / 10 to MIRO. When comparing the yearly performance of all stocks, MIRO is one of the better performing stocks in the market, outperforming 96.98% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to MIRO. MIRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months MIRO reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 17.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| Debt/Equity | 0.03 |
8 analysts have analysed MIRO and the average price target is 3.19 USD. This implies a price decrease of -5.97% is expected in the next year compared to the current price of 3.39.
For the next year, analysts expect an EPS growth of 32.47% and a revenue growth -6.67% for MIRO
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 20.81 | 191.962B | ||
| DHR | DANAHER CORP | 24.83 | 148.096B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 141.98 | 46.374B | ||
| A | AGILENT TECHNOLOGIES INC | 20.52 | 34.761B | ||
| IQV | IQVIA HOLDINGS INC | 12.41 | 28.089B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 30.14 | 28.006B | ||
| WAT | WATERS CORP | 22.66 | 19.843B | ||
| ILMN | ILLUMINA INC | 23.28 | 17.98B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.11 | 17.346B | ||
| MEDP | MEDPACE HOLDINGS INC | 26.47 | 12.783B |
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company is headquartered in Eden Prairie, Minnesota and currently employs 76 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.
MIROMATRIX MEDICAL INC
6455 Flying Cloud Drive, Suite 107
Eden Prairie MINNESOTA US
CEO: Jeff Ross
Employees: 76
Phone: 16122027026
Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company is headquartered in Eden Prairie, Minnesota and currently employs 76 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.
The current stock price of MIRO is 3.39 USD. The price increased by 0.59% in the last trading session.
MIRO does not pay a dividend.
MIRO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
8 analysts have analysed MIRO and the average price target is 3.19 USD. This implies a price decrease of -5.97% is expected in the next year compared to the current price of 3.39.
MIROMATRIX MEDICAL INC (MIRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MIRO.